---
title: "Lishan Aklog Discloses Investment at PAVmed Inc. with 5.1% Stake"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/282268119.md"
description: "Lishan Aklog, M.D., Chairman and CEO of PAVmed Inc., disclosed a 5.1% stake in the company’s common stock, as per a Schedule 13D filed on April 9, 2026. The filing includes a grant of 350,000 restricted shares and indicates Aklog's intent to hold the shares for investment purposes, with no current plans for mergers or control changes. Aklog, a physician and entrepreneur, focuses on medical device investments and may adjust his holdings over time."
datetime: "2026-04-10T01:06:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/282268119.md)
  - [en](https://longbridge.com/en/news/282268119.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/282268119.md)
---

# Lishan Aklog Discloses Investment at PAVmed Inc. with 5.1% Stake

Lishan Aklog, M.D., Chairman and CEO of PAVmed Inc., disclosed beneficial ownership of a 5.1% stake in PAVmed Inc.’s common stock. The Schedule 13D reflects holdings as of April 2, 2026, and was filed on April 9, 2026. The filing highlights a new grant of 350,000 restricted shares and clarifies his current intentions as an investor.

**Investor Intent**

Aklog holds the shares for investment purposes and may buy or sell more over time, including through options. He states he "has no plans or proposals" for actions like mergers, asset sales, board changes, or other control moves at this time.

The company granted him 350,000 shares of restricted stock on April 2, 2026, under its long-term incentive plan. He also holds options for additional shares and may adjust his position as circumstances change.

**Investor's Background**

Lishan Aklog, M.D., is an American physician and medical technology entrepreneur. He serves as Chairman and Chief Executive Officer of PAVmed Inc. and also leads its subsidiary, Lucid Diagnostics Inc. He focuses on building and investing in medical device and diagnostics businesses with a long-term, operator-led approach.

Original SEC Filing: PAVmed Inc. \[ PAVM \] - SCHEDULE 13D - Apr. 09, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [XHE.US](https://longbridge.com/en/quote/XHE.US.md)
- [PAVM.US](https://longbridge.com/en/quote/PAVM.US.md)
- [IHI.US](https://longbridge.com/en/quote/IHI.US.md)

## Related News & Research

- [PAVmed Reports Q1 2026 Results and Business Update](https://longbridge.com/en/news/286567652.md)
- [Analyst Reaffirms Buy on PAVmed, Citing Oncology Platform Momentum and Partnerships; Price Target Maintained at $16](https://longbridge.com/en/news/286945953.md)
- [Richards Group Inc. Announces May 2026 Dividend | RPKIF Stock News](https://longbridge.com/en/news/286925142.md)
- [AleAnna, Inc. Reports First Quarter 2026 Results | ANNA Stock News](https://longbridge.com/en/news/286463118.md)
- [Capstone Companies, Inc. announces Execution of Binding Letter of Intent with eBliss Global, Inc. | CAPC Stock News](https://longbridge.com/en/news/286782166.md)